Allogene Therapeutics
Sylvie Dinh is a seasoned finance professional with extensive experience in Financial Planning and Analysis (FP&A) and accounting. Currently serving as the Senior Manager of FP&A at Allogene Therapeutics since April 2025, Sylvie previously held roles at BridgeBio, including Senior Manager and FP&A Manager. Prior to that, Sylvie was the Accounting Manager at Exym and contributed to finance and operations at ASG. Sylvie's career also includes positions as Senior Accountant at Aimmune Therapeutics, where the company was acquired by Nestlé Health Science, and as an Accountant at Cleave Therapeutics, Inc. and CH Reynolds. Sylvie Dinh holds a Bachelor's Degree in Business Administration with a focus on Accounting from San José State University.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.